# CRC01

Source: https://onco.cc/drugs/crc01/  
OnCo record `crc01` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRC01 is an experimental CAR-T cell therapy from Curocell in phase 2 trials for diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia, aimed at CD19.

## Summary

CRC01 is a CAR-T cell therapy developed by Curocell. Its target is CD19 (the sponsor names CD19). The sponsor states: A single intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells directed against CD19, engineered with PD-1 and TIGIT knock-down to enhance T-cell effector function, given after fludarabine/cyclophosphamide conditioning. ClinicalTrials.gov describes the intervention as: Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-t. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. The largest, NCT04836507, plans to enrol 91 participants with primary completion expected 2030-08-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: A single intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells directed against CD19, engineered with PD-1 and TIGIT knock-down to enhance T-cell effector function, given after fludarabine/cyclophosphamide conditioning.

## Sources

- ClinicalTrials.gov: trials of CRC01: https://clinicaltrials.gov/search?intr=CRC01

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- trials: [Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients](https://onco.cc/trials/nct04836507/)
- key papers: [Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)](https://onco.cc/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/crc01.json